Biomarkers of cardiac stress or damage (either NT-proBNP or hs-cTnT, or other biomarkers) may identify a subgroup of patients with earlier stage AS who may benefit from early AVR, but among patients with asymptomatic high-gradient severe AS, NT-proBNP and hs-cTnT levels do not appear to be particularly useful for guiding clinical decision making on the timing of TAVR. This evidence concerns the gene TNNT2 and aortic stenosis.